Cardiac-Valvular Ehlers-Danlos Syndrome · cvEDS

Description

Cardiac-valvular Ehlers-Danlos syndrome, cvEDS, is a rare autosomal recessive connective tissue disorder caused by biallelic null variants in COL1A2, the gene that encodes the pro-alpha 2 chain of type I collagen. When both COL1A2 alleles are null, no pro-alpha 2(I) chain is produced, and type I collagen assembles instead as alpha 1(I) homotrimers. The homotrimer is structurally and biomechanically abnormal, and the cardiac valves bear the brunt of the defect.

The 2017 international classification (Malfait et al., American Journal of Medical Genetics Part C, 2017) defines cvEDS by major criteria that include severe progressive cardiac valvular disease involving the aortic and mitral valves, skin involvement consistent with EDS such as hyperextensibility, atrophic scars, and easy bruising, and joint hypermobility, generalized or limited to small joints. Molecular confirmation requires biallelic COL1A2 variants that fully abolish pro-alpha 2(I) production, typically through nonsense, frameshift, or splice variants on both alleles. The syndrome was characterized as a distinct entity by Schwarze et al. (American Journal of Human Genetics, 2004) on the basis of biochemistry and inheritance pattern.

The contrast with osteogenesis imperfecta is mechanistically informative. Heterozygous COL1A2 variants, particularly missense changes affecting glycine residues in the triple helix, cause osteogenesis imperfecta through a dominant-negative effect on collagen assembly. Biallelic null variants on the same gene cause cvEDS through a different mechanism, the production of homotrimeric collagen, with a different clinical picture centered on cardiac valves rather than bone. Brittle bone disease and severe valvular disease arise from the same gene through different molecular consequences.

Fewer than 20 affected individuals have been reported across the literature since the original description. Prevalence estimates are not meaningful at this case count.

Treatments to date

No drug therapy modifies the underlying collagen defect in cvEDS. Clinical care centers on lifelong cardiac surveillance and timely valve replacement.

Baseline cardiac evaluation at diagnosis includes echocardiography to characterize valve structure and function and to establish a reference for serial imaging. Surveillance echocardiography is repeated on an interval set by the cardiologist, with shorter intervals as valve disease progresses. The mitral and aortic valves are most often involved, and progression to severe regurgitation requiring surgical replacement is the dominant clinical course. Valve replacement is performed using mechanical or bioprosthetic valves following standard cardiac surgical practice. Surgical outcomes are described in case reports given the small number of affected individuals, and operative planning accounts for the connective tissue fragility documented across EDS subtypes, including tissue friability and altered wound healing.

Skin care follows the broader EDS playbook of wound protection, careful suturing, and attention to atrophic scars. Joint hypermobility is managed conservatively with physical therapy and activity modification. Pregnancy in affected women requires coordinated cardiology and high-risk obstetric care given the hemodynamic load on already abnormal valves.

Genetic counseling addresses the autosomal recessive inheritance pattern, with a 25 percent recurrence risk for offspring of two carrier parents and confirmed carrier status for both biological parents of an affected individual. Prenatal and preimplantation genetic testing are available when familial variants are known.

No disease-specific drug or registered clinical trial in cvEDS exists. Research directions named by recent reviews include the biomechanics of homotrimeric type I collagen, the determinants of valvular versus skeletal phenotype across COL1A2 variant classes, and registry-scale natural history data to guide surveillance intervals and the timing of valve replacement.